Looking to the Future of Organ-on-Chip and Toxicity Assessment: a Regulator’s Opinion

Jones, David R.

doi:10.4155/fsoa-2016-0068

Cited by 4 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International regulatory agencies have begun to advocate for the increased incorporation of 3D human cell-based models as a central screening assay within the pharmaceutical drug discovery process [18]. It is anticipated that such 3D models will reduce the reliance on in vivo animal models while increasing the efficiency for the identification of effective therapeutic target compounds [19].…”

Section: Discussionmentioning

confidence: 99%

Human Adipose Derived Cells in Two- and Three-Dimensional Cultures: Functional Validation of an In Vitro Fat Construct

Bender

McCarthy

Brown

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Obesity, defined as a body mass index of 30 kg/m2 or above, has increased considerably in incidence and frequency within the United States and globally. Associated comorbidities including cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, and nonalcoholic fatty liver disease have led to a focus on the mechanisms promoting the prevention and treatment of obesity. Commonly utilized in vitro models employ human or mouse preadipocyte cell lines in a 2-dimensional (2D) format. Due to the structural, biochemical, and biological limitations of these models, increased attention has been placed on “organ on a chip” technologies for a 3-dimensional (3D) culture. Herein, we describe a method employing cryopreserved primary human stromal vascular fraction (SVF) cells and a human blood product-derived biological scaffold to create a 3D adipose depot in vitro. The “fat-on-chip” 3D cultures have been validated relative to 2D cultures based on proliferation, flow cytometry, adipogenic differentiation, confocal microscopy/immunofluorescence, and functional assays (adipokine secretion, glucose uptake, and lipolysis). Thus, the in vitro culture system demonstrates the critical characteristics required for a humanized 3D white adipose tissue (WAT) model.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Adipose Derived Cells in Two- and Three-Dimensional Cultures: Functional Validation of an In Vitro Fat Construct

Bender

McCarthy

Brown

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…The reviews herein highlight the potential use of OOAC devices by the pharmaceutical industry in drug development. The fourth article by Eva-Marie Dehne and colleagues entitled, “ The ascendance of microphysiological systems to solve the drug testing dilemma ” looks at the topic from an industry perspective and importantly highlights the role that regulatory bodies play [ 10 ]; as any shift to a new technology will require full acceptance by a number of national and international bodies [ 11 ]. The review particularly discusses how the microfluidic platforms address the ADME (absorption, distribution, metabolism and excretion) criteria that are core to the pharmacology community.…”

mentioning

confidence: 99%